PMID- 27620179
OWN - NLM
STAT- MEDLINE
DCOM- 20170213
LR  - 20211204
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 15
IP  - 1
DP  - 2016 Sep 13
TI  - Different relationship between ANGPTL3 and HDL components in female non-diabetic 
      subjects and type-2 diabetic patients.
PG  - 132
LID - 10.1186/s12933-016-0450-1 [doi]
LID - 132
AB  - BACKGROUND: Angiopoietin-like protein 3 (ANGPTL3) is a major lipoprotein 
      regulator and shows positive correlation with high-density 
      lipoprotein-cholesterol (HDL-c) in population studies and ANGPTL3 mutated 
      subjects. However, no study has looked its correlation with HDL components nor 
      with HDL function in patients with type 2 diabetes mellitus (T2DM). METHODS: We 
      studied 298 non-diabetic subjects and 300 T2DM patients who were randomly 
      recruited in the tertiary referral centre. Plasma levels of ANGPTL3 were 
      quantified by ELISA. Plasma samples were fractionated to obtain HDLs. HDL 
      components including apolipoprotein A-I (apoA-I), triglyceride, serum amyloid A 
      (SAA), phospholipid and Sphingosine-1-phosphate were measured. HDLs were isolated 
      from female controls and T2DM patients by ultracentrifugation to assess 
      cholesterol efflux against HDLs. A Pearson unadjusted correlation analysis and a 
      linear regression analysis adjusting for age, body mass index and lipid lowering 
      drugs were performed in male or female non-diabetic participants or diabetic 
      patients, respectively. RESULTS: We demonstrated that plasma level of ANGPTL3 was 
      lower in female T2DM patients than female controls although no difference of 
      ANGPTL3 levels was detected between male controls and T2DM patients. After 
      adjusting for confounding factors, one SD increase of ANGPTL3 (164.6 ng/ml) 
      associated with increase of 2.57 mg/dL cholesterol and 1.14 mug/mL apoA-I but 
      decrease of 47.07 mug/L of SAA in HDL particles of non-diabetic females (p < 0.05 
      for cholesterol and SAA; p < 0.0001 for apoA-I). By contrast, 1-SD increase of 
      ANGPTL3 (159.9 ng/ml) associated with increase of 1.69 mg/dl cholesterol and 
      1.25 mug/mL apoA-I but decrease of 11.70 mug/L of SAA in HDL particles of female 
      diabetic patients (p < 0.05 for cholesterol; p < 0.0001 for apoA-I; p = 0.676 for 
      SAA). Moreover, one SD increase of ANGPTL3 associated with increase of 2.11 % 
      cholesterol efflux against HDLs in non-diabetic females (p = 0.071) but decrease 
      of 1.46 % in female T2DM patients (p = 0.13) after adjusting for confounding 
      factors. CONCLUSIONS: ANGPTL3 is specifically correlated with HDL-c, apoA-I, SAA 
      and HDL function in female non-diabetic participants. The decrease of ANGPTL3 
      level in female T2DM patients might contribute to its weak association to HDL 
      components and function. ANGPTL3 could be considered as a novel therapeutic 
      target for HDL metabolism for treating diabetes.
FAU - Zhao, Dong
AU  - Zhao D
AD  - Beijing Key Laboratory of Diabetes Prevention and Research, Department of 
      Endocrinology, Lu He Hospital, Capital Medical University, Beijing, 101149, 
      China.
FAU - Yang, Long-Yan
AU  - Yang LY
AD  - Beijing Key Laboratory of Diabetes Prevention and Research, Department of 
      Endocrinology, Lu He Hospital, Capital Medical University, Beijing, 101149, 
      China.
FAU - Wang, Xu-Hong
AU  - Wang XH
AD  - Beijing Key Laboratory of Diabetes Prevention and Research, Department of 
      Endocrinology, Lu He Hospital, Capital Medical University, Beijing, 101149, 
      China.
FAU - Yuan, Sha-Sha
AU  - Yuan SS
AD  - Beijing Key Laboratory of Diabetes Prevention and Research, Department of 
      Endocrinology, Lu He Hospital, Capital Medical University, Beijing, 101149, 
      China.
FAU - Yu, Cai-Guo
AU  - Yu CG
AD  - Beijing Key Laboratory of Diabetes Prevention and Research, Department of 
      Endocrinology, Lu He Hospital, Capital Medical University, Beijing, 101149, 
      China.
FAU - Wang, Zong-Wei
AU  - Wang ZW
AD  - Beijing Key Laboratory of Diabetes Prevention and Research, Department of 
      Endocrinology, Lu He Hospital, Capital Medical University, Beijing, 101149, 
      China.
FAU - Lang, Jia-Nan
AU  - Lang JN
AD  - Beijing Key Laboratory of Diabetes Prevention and Research, Department of 
      Endocrinology, Lu He Hospital, Capital Medical University, Beijing, 101149, 
      China.
FAU - Feng, Ying-Mei
AU  - Feng YM
AD  - Beijing Key Laboratory of Diabetes Prevention and Research, Department of 
      Endocrinology, Lu He Hospital, Capital Medical University, Beijing, 101149, 
      China. yingmeif13@sina.com.
AD  - Stem Cell Institute, University of Leuven, 3000, Louvain, Belgium. 
      yingmeif13@sina.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160913
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (ANGPTL3 protein, human)
RN  - 0 (APOA1 protein, human)
RN  - 0 (Angiopoietin-Like Protein 3)
RN  - 0 (Angiopoietin-like Proteins)
RN  - 0 (Angiopoietins)
RN  - 0 (Angptl3 protein, mouse)
RN  - 0 (Apolipoprotein A-I)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Serum Amyloid A Protein)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Angiopoietin-Like Protein 3
MH  - Angiopoietin-like Proteins
MH  - Angiopoietins/*blood
MH  - Animals
MH  - Apolipoprotein A-I/blood
MH  - Biomarkers/blood
MH  - Blood Glucose/metabolism
MH  - Body Mass Index
MH  - Case-Control Studies
MH  - Cells, Cultured
MH  - Cholesterol, HDL/*blood
MH  - Diabetes Mellitus, Type 2/*blood/diagnosis/drug therapy
MH  - Disease Models, Animal
MH  - Down-Regulation
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Hepatocytes/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Hypolipidemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Linear Models
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Serum Amyloid A Protein/analysis
MH  - Sex Factors
MH  - Tertiary Care Centers
PMC - PMC5020513
OTO - NOTNLM
OT  - Angiopoietin-like protein
OT  - Apolipoproteins
OT  - Cholesterol efflux
OT  - Diabetes
OT  - High-density lipoproteins
OT  - Serum amyloid A
EDAT- 2016/09/14 06:00
MHDA- 2017/02/14 06:00
PMCR- 2016/09/13
CRDT- 2016/09/14 06:00
PHST- 2016/07/22 00:00 [received]
PHST- 2016/09/03 00:00 [accepted]
PHST- 2016/09/14 06:00 [entrez]
PHST- 2016/09/14 06:00 [pubmed]
PHST- 2017/02/14 06:00 [medline]
PHST- 2016/09/13 00:00 [pmc-release]
AID - 10.1186/s12933-016-0450-1 [pii]
AID - 450 [pii]
AID - 10.1186/s12933-016-0450-1 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2016 Sep 13;15(1):132. doi: 10.1186/s12933-016-0450-1.